Ongoing SCENESSE® Clinical Trials

Clinuvel is currently conducting one clinical trial of SCENESSE® (afamelanotide 16mg) as a repigmentation therapy in generalised vitiligo. A physician-led study of SCENESSE® in Hailey-Hailey Disease commenced in early 2014.

In February 2012 Clinuvel filed a marketing authorisation application (MAA) for SCENESSE® with the European Medicines Agency for the orphan disease erythropoietic protoporphria (EPP).

Clinuvel Stock Ticker

Quick Links